Trinidad and TobagoTuberculosis profile
Population  2015 1.4 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.021 (0.019–0.023) 1.5 (1.4–1.7)
Mortality (HIV+TB only) <0.01 (<0.01–0.014) 0.46 (0.12–1)
Incidence  (includes HIV+TB) 0.23 (0.19–0.26) 17 (14–19)
Incidence (HIV+TB only) 0.039 (0.033–0.045) 2.9 (2.4–3.3)
Incidence (MDR/RR-TB)** 0.01 (<0.01–0.012) 0.74 (0.59–0.88)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females <0.01 (<0.01–0.013) 0.066 (0.042–0.091) 0.075 (0.047–0.1)
Males <0.01 (<0.01–0.012) 0.14 (0.11–0.17) 0.15 (0.12–0.18)
Total 0.018 (0.014–0.022) 0.21 (0.19–0.23) 0.23 (0.19–0.26)
TB case notifications, 2015  
Total cases notified 218
Total new and relapse 196
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 94%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.09–0.16)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 32 16%
          - on antiretroviral therapy 16 50%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  9
(7–10)
Estimated % of TB cases with MDR/RR-TB 2.3% (1.4–3.2) 15% (13–18)  
% notified tested for rifampicin resistance 36% 32% 78
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 2, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 64% 251
Previously treated cases, excluding relapse, registered in 2014 29% 42
HIV-positive TB cases, all types, registered in 2014 44% 63
MDR/RR-TB cases started on second-line treatment in 2013 71% 7
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment <1%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data